## Hypertensive disorders of pregnancy – what do I think?

Hypertensive disorders of pregnancy represent major causes of maternal and fœtal morbidity and mortality, affecting 10-15% of all pregnancies (pre-eclampsia 3-10%). Pre-eclampsia, particularly in its severe forms with intra-uterine growth retardation and prematurity, has to be considered as a cardiovascular and renal risk factor. Pre-eclampsia doubles the risk of stroke and ischemic cardiopathy, renal disease in the next 5-15 years, et multiplies by four the occurrence of a fixed hypertension. So, the guidelines of the ESH 2013 recommand to take into account the obstetrical history (hypertension, preeclampsia, gestationnal diabetes, intra-uterine growth retardation, prematurity, child low birth weight) in the cardiovascular anamnesis of a woman. The different presentations of hypertension during pregnancy are :

- Preexistant hypertension (primary or secondary) : BP (blood pressure) ≥140/90mmHg before pregnancy, or HTN (hypertension) before 20 amenorrhea weeks (AW), or antihypertensive treatment before pregnancy ; ± proteinuria; persists in the postpartum.
- Gestational HTN : HTN *de novo* ≥140/90mmHg after 20 AW ; absence of proteinuria; resolution in the post-partum.
- Preeclampsia, eclampsia : ≥140/90mmHg after 20 AW ; proteinuria with proteine/creatinine urine spot ratio ≥30 (cave 10% with no proteinuria, but other organ damage). Edema is not any more a criterion, neither the BP difference before/during pregnancy.
- Preeclampsia superimposed on chronic HTN: worsening of known HTN and proteinuria ± other organ damage.

The other organs that may be damaged are essentially: the central nervous system (comprising severe headache), hepatic capsule distension, hepatic tests alterations (sometimes HELLP), thrombocytopenia, hemolytic anemia, renal failure, intra-uterine growth retardation, acute pulmonary edema, heart failure. Some preeclampsia occur in the post-partum period.

ESH 2013 guidelines recommand medical antihypertensive treatment during pregnancy if BP  $\geq$ 150/95mmHg, if gestational HTN and BP  $\geq$ 140/90mmHg, if organ damage and/or symptoms (Class IIb, evidence level C).

Antihypertensive medications allowed during pregnancy :

- 2-methyldopa (central agonist 22-adrenergic central) (class B) : medication of choice because of proved long-term security. Practically : side effects and low efficacy. Breasfeeding +
- Labetalol (non-selective 2-blocker, with 2-blocker activity (class C). Breasfeeding +
- Nifedipine slow release. Cave hypotension with magnesium sulfate. Breastfeeding +
- Hydrochlorothiazide (class B) : useful in case of HTN preexisting before pregnancy (can be continued). Cave : intravascular volume contraction. May reduce breastfeeding.
- Other alternatives : prazosine, clonidine.
- D-blockers, particularly atenolol (class D) are not recommended because of intra-uterine growth retardation (except oxprenolol class B). Breatsfeeding –

All renin-angiotensin-aldosterone system blockers, including aliskiren et spironolactone are againstindicated during pregnancy.

On the other hand, enalapril and benazepril are compatible with breastfeeding.

In high risk preeclampsia patients (pre-existing HTN, ages <20 years ou >40 years, diabetes mellitus, renal disease, history of preeclampsia, thrombophilia...) aspirine 100mg/d is recommended from 12 AW for preeclampsia prevention (if unaugmented hemorragic risk). (IIb).

Swiss Society of Hypertension / June 2017